Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People as Young as Six Months - Canada NewsWire

/CNW/ -- Seqirus, a global leader in influenza prevention, announced today that it has received Health Canada approval of FLUCELVAX® QUAD (Influenza Vaccine),...

A Phase 3 clinical study supported the expanded age indication, demonstrating that FLUCELVAX® QUAD was as safe and immunogenic as a standard quadrivalent seasonal influenza vaccine (QIV) in children … [+5951 chars]

full article...